The ASCO Post

1 week ago | ascopost.com | Jo Cavallo

At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she can’t explain where the idea came from. She just knows the desire to help others was ingrained in her from a very early age. Growing up in New Delhi, India, where education and personal achievement rank high on the list of family priorities, Dr. Aggarwal felt a great sense of wanting to be of service.

1 week ago | ascopost.com | Matthew Stenger

In a phase III trial (CheckMate 9DW) reported in The Lancet, Yau et al evaluated whether first-line nivolumab plus ipilimumab improved overall survival vs investigator's choice of lenvatinib or sorafenib in patients with unresectable hepatocellular carcinoma.

1 week ago | ascopost.com | Matthew Stenger

In a single-center phase I trial reported in The New England Journal of Medicine, Svoboda et al assessed the safety, feasibility, and preliminary efficacy of an enhanced chimeric antigen receptor (CAR) T-cell therapy (huCART19-IL18) in patients with relapsed or refractory lymphoma after previous anti-CD19 CAR T-cell therapy. As stated by the investigators, “…CAR T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission.

1 week ago | ascopost.com | Matthew Stenger

In a Belgian phase III trial (ROBOMET) reported in the Journal of Clinical Oncology, Mercier et al attempted to determine whether dose-escalated, single-fraction stereotactic body radiotherapy was associated with statistically significant benefit vs conventional, single-fraction, 3D conformal radiotherapy in the 1-month rate of complete pain response in patients with painful bone metastases.

1 week ago | ascopost.com | Matthew Stenger

In a Danish Breast Cancer Group nationwide prospective cohort study reported in The Lancet Oncology, Jensen et al attempted to develop a prognostic standard mortality rate index to predict excess mortality based on risk-adapted adjuvant therapy in postmenopausal patients with early-stage breast cancer.